Geode Capital Management, LLC Replimune Group, Inc. Transaction History

Geode Capital Management, LLC

$1.39 Trillion
Q2 2025

A detailed history of Geode Capital Management, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,624,048 shares of REPL stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,624,048

Previous 1,672,770 2.91%

Holding current value

$14.5 Million

Previous $16.3 Million 7.49%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$6.92 - $10.38 $337,156 - $505,734	-48,722 Reduced 2.91%	1,624,048 $15.1 Million
Q1 2025 May 13, 2025	BUY	$9.75 - $14.31 $2.37 Million - $3.48 Million	243,104 Added 17.0%	1,672,770 $16.3 Million
Q4 2024 Feb 12, 2025	BUY	$10.54 - $14.93 $14,387 - $20,379	1,365 Added 0.1%	1,429,666 $17.3 Million
Q3 2024 Nov 12, 2024	BUY	$8.09 - $11.23 $1.76 Million - $2.44 Million	217,308 Added 17.94%	1,428,301 $15.7 Million
Q2 2024 Aug 09, 2024	BUY	$5.01 - $9.46 $96,192 - $181,632	19,200 Added 1.61%	1,210,993 $10.9 Million
Q1 2024 May 13, 2024	BUY	$6.87 - $9.31 $320,698 - $434,600	46,681 Added 4.08%	1,191,793 $9.74 Million
Q4 2023 Feb 13, 2024	BUY	$6.75 - $16.18 $923,190 - $2.21 Million	136,769 Added 13.56%	1,145,112 $9.65 Million
Q3 2023 Nov 13, 2023	BUY	$15.96 - $22.18 $3.31 Million - $4.6 Million	207,515 Added 25.91%	1,008,343 $17.3 Million
Q2 2023 Aug 11, 2023	SELL	$15.65 - $24.1 $413,410 - $636,625	-26,416 Reduced 3.19%	800,828 $18.6 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $2.24 Million - $3.73 Million	128,099 Added 18.32%	827,244 $14.6 Million
Q4 2022 Feb 13, 2023	BUY	$17.09 - $27.91 $241,515 - $394,424	14,132 Added 2.06%	699,145 $19 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $2.25 Million - $3.05 Million	144,297 Added 26.69%	685,013 $11.8 Million
Q2 2022 Aug 12, 2022	SELL	$13.32 - $19.98 $21,085 - $31,628	-1,583 Reduced 0.29%	540,716 $9.45 Million
Q1 2022 May 13, 2022	BUY	$15.24 - $29.75 $268,696 - $524,522	17,631 Added 3.36%	542,299 $9.21 Million
Q4 2021 Feb 11, 2022	BUY	$25.43 - $34.25 $639,869 - $861,798	25,162 Added 5.04%	524,668 $14.2 Million
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $861,053 - $1.17 Million	29,712 Added 6.32%	499,506 $14.8 Million
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $1.08 Million - $1.49 Million	37,865 Added 8.77%	469,794 $18 Million
Q1 2021 May 12, 2021	BUY	$30.22 - $45.57 $1.54 Million - $2.33 Million	51,037 Added 13.4%	431,929 $13.2 Million
Q4 2020 Feb 12, 2021	BUY	$23.5 - $52.65 $2.12 Million - $4.74 Million	90,086 Added 30.98%	380,892 $14.5 Million
Q3 2020 Nov 13, 2020	BUY	$18.85 - $27.0 $1.5 Million - $2.14 Million	79,343 Added 37.52%	290,806 $6.69 Million
Q2 2020 Aug 13, 2020	BUY	$9.76 - $25.95 $289,091 - $768,639	29,620 Added 16.29%	211,463 $5.25 Million
Q1 2020 May 14, 2020	BUY	$8.9 - $19.08 $146,912 - $314,953	16,507 Added 9.98%	181,843 $1.81 Million
Q4 2019 Feb 13, 2020	BUY	$11.61 - $17.21 $366,643 - $543,491	31,580 Added 23.61%	165,336 $2.37 Million
Q3 2019 Nov 12, 2019	BUY	$10.01 - $16.87 $24,394 - $41,112	2,437 Added 1.86%	133,756 $1.86 Million
Q2 2019 Aug 14, 2019	BUY	$12.51 - $17.28 $218,462 - $301,760	17,463 Added 15.34%	131,319 $1.93 Million
Q1 2019 May 14, 2019	BUY	$10.26 - $16.24 $627,593 - $993,384	61,169 Added 116.1%	113,856 $1.73 Million
Q4 2018 Feb 13, 2019	BUY	$9.97 - $15.57 $68,573 - $107,090	6,878 Added 15.01%	52,687 $526,000
Q3 2018 Nov 13, 2018	BUY	$14.99 - $22.14 $686,676 - $1.01 Million	45,809 New	45,809 $737,000

Others Institutions Holding REPL

# of Institutions

196

Shares Held

77.5M

Call Options Held

2.06M

Put Options Held

2.86M

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $441M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Replimune Group, Inc. Transaction History